Form PTO		U.S. DEPARTA	OF COMME		ATTY. DOCKET NO.		₼95RIAI™	(O) O E	47
(MODIFIED) PATENT AND THE EMARK OFFICE					078883/011 097508516NED 6				
IN	IFORMA	TION DISCLOSU	RE CITATION	APPLICANG Hec'd PCT/PTO 2 4 MAR 2000 Christopher Robert BEBBINGTON et al.					
				FILING DATE GROUP ART UNIT					
	(Use	several sheets if ned	essary)	March 24, 2000		UNASSIGNED			
			U.S. P.	ATEN	T DOCUMENTS	1/1	ach #	5	ED
INITIAL	REF	DOCUMENT NUMBER	DATE :		NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	+		-						
	_		-				-		
				_					
	+								
			FOREIGN	PATE	NT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB-	TRANSLATION	
Cui	A1	96/28563	09/1996	WIPO			CLASS	YES	NO
_mJ	A2	98/15636	04/1998	WIPO					
		MODGENOTED:	MENTS (Includin	g Auti	hor, Title, Date, Pertin	ent Pages, E	tc.)		
m)	АЗ	MORGENSTERN J.P., et al, "Advanced mammalian gene transfer: high titre retroviral vectors with multiple							
		drug selection markers and a complementary helper-free packaging cell line, <i>Nucleic Acids Research</i> , Vol. 18, No. 12, pp. 3587-3596, (May 7, 1990)							
W)	A4	BILBAO, G., et al, "Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable							
		transduction in vivo, The FASEB Journal, Vol. 11, pp. 624-634. (July 11, 1997)							
m), I	A5	Promega Product (255, (1997)						
W/	A6	ZHENG, B, et al., "Increment of hFIX expression with endogenous intron 1 in vitro1", Cell Research, Vol. 7, No. 1, pp. 21-29, (June 1997)							
XAMINER		Min	<u> </u>	I	DATE CONSIDERED	2			-
* EXAM	INER:	Initial if citation co	onsidered, whe	ther c	or not citation is in c	onformance	e with MPE	P 609:	Draw
comm	nunicatio	on to applicant.	simunce an	iu 1101	or not citation is in c t considered. Includ	le any copy	of this fo	m with	next

002.319363